AREV Life Sciences Global Corp.
AREVF
$0.01
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 5.30K | 17.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 5.30K | 17.70K |
| Cost of Revenue | -- | -- | -- | 14.70K | -- |
| Gross Profit | -- | -- | -- | -9.40K | 17.70K |
| SG&A Expenses | -1.40K | 55.10K | 107.70K | -103.00K | 153.10K |
| Depreciation & Amortization | 10.30K | 10.30K | 10.20K | 21.20K | 24.90K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.90K | 85.60K | 117.90K | -62.20K | 182.00K |
| Operating Income | -8.90K | -85.60K | -117.90K | 67.50K | -164.30K |
| Income Before Tax | -21.60K | -89.90K | -125.20K | 58.60K | -184.40K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.60K | -89.90K | -125.20K | 58.60K | -184.40K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.60K | -89.90K | -125.20K | 58.60K | -184.40K |
| EBIT | -8.90K | -85.60K | -117.90K | 67.50K | -164.30K |
| EBITDA | 1.40K | -75.30K | -107.70K | 80.00K | -139.40K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 31.76M | 31.76M | 31.72M | 31.51M | 30.57M |
| Average Diluted Shares Outstanding | 31.76M | 31.76M | 31.72M | 31.51M | 30.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |